Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Telbivudine vs Adefovir in HBeAg-Positive Chronic Hepatitis B
NCT00115245Phase 3Completed
- Sponsor
- Novartis
- Start
- Nov 2004
- Primary completion
- Aug 2006
- Modality
- Orthosteric Ligands, Metabolically Activated Prodrugs
- Countries
- 9
01
Overview
Phase 3, randomised, open-label trial of telbivudine in Chronic Hepatitis B (CHB) (3 arms), sponsored by Novartis. Primary endpoint: Reduction in Serum HBV DNA at 24 weeks. Started Nov 2004; status: completed.
02
Drugs
telbivudine
03
Conditions
Chronic Hepatitis B (CHB)
Beyond the preview
Go deeper on NCT00115245.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00115245.